Publications by authors named "Thomas Hawthorne"

Claim this Profile
S
Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study.
Martin Metz, Sonja Ständer, Ali Moiin, Leigh Nattkemper, Bradley Bloom, Thomas Hawthorne

J Am Acad Dermatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the Kinetics of Human Skin Mast Cell Depletion and Repopulation Following KIT Inhibition.
Diego Alvarado, Deena M Maurer, Philip Golden, Thomas Hawthorne, Lawrence J Thomas

Allergy· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria.
Marcus Maurer, Martin Metz, John Anderson, Neetu Talreja, Diane Young, Thomas Hawthorne

Allergy· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria.
Dorothea Terhorst-Molawi, Tomasz Hawro, Eva Grekowitz, Lea Kiefer, Kunal Merchant, Thomas Hawthorne

Allergy· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study.
Diego Alvarado, Marcus Maurer, Richard Gedrich, Scott B Seibel, Michael B Murphy, Thomas R Hawthorne

Allergy· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Thomas R Hawthorne

J Immunother Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
Linda T Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L Telli, Thomas Hawthorne

NPJ Breast Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma.
Bradley A McGregor, Michael Gordon, Ronan Flippot, Neeraj Agarwal, Saby George, Thomas Hawthorne

Invest New Drugs· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.
Nina Bhardwaj, Philip A Friedlander, Anna C Pavlick, Marc S Ernstoff, Brian R Gastman, Thomas Hawthorne

Nat Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.
Stephen M Ansell, Ian Flinn, Matthew H Taylor, Branimir I Sikic, Joshua Brody, Thomas R Hawthorne

Blood Adv· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
Lisa M Kopp, Suman Malempati, Mark Krailo, Yun Gao, Allen Buxton, Thomas Hawthorne

Eur J Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.
Umamaheswar Duvvuri, Jonathan George, Seungwon Kim, Diego Alvarado, Veronique M Neumeister, Thomas Hawthorne

Clin Cancer Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Patrick A Ott, Anna C Pavlick, Douglas B Johnson, Lowell L Hart, Jeffrey R Infante, Thomas R Hawthorne

Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.
Bernadette V Marquez-Nostra, Supum Lee, Richard Laforest, Laura Vitale, Xingyu Nie, Thomas Hawthorne

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
Howard A Burris, Jeffrey R Infante, Stephen M Ansell, John J Nemunaitis, Geoffrey R Weiss, Thomas R Hawthorne

J Clin Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
April A N Rose, Matthew G Annis, Dennie T Frederick, Marco Biondini, Zhifeng Dong, Thomas Hawthorne

Clin Cancer Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
Marina Caskey, Florian Klein, Julio C C Lorenzi, Michael S Seaman, Anthony P West, Thomas Hawthorne

Nature· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
Johannes F Scheid, Joshua A Horwitz, Yotam Bar-On, Edward F Kreider, Ching-Lan Lu, Thomas Hawthorne

Nature· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Arman Esfandiari, Thomas A Hawthorne, Sirintra Nakjang, John Lunec

Mol Cancer Ther· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
Michael Roth, David M Barris, Sajida Piperdi, Vicky Kuo, Stephanie Everts, Thomas Hawthorne

Pediatr Blood Cancer· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
Marina Caskey, Florian Klein, Julio C C Lorenzi, Michael S Seaman, Anthony P West, Thomas Hawthorne

Nature· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
Denise A Yardley, Robert Weaver, Michelle E Melisko, Mansoor N Saleh, Francis P Arena, Thomas Hawthorne

J Clin Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.
Patrick A Ott, Omid Hamid, Anna C Pavlick, Harriet Kluger, Kevin B Kim, Thomas Hawthorne

J Clin Oncol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
E Anders Kolb, Richard Gorlick, Catherine A Billups, Thomas Hawthorne, Raushan T Kurmasheva

Pediatr Blood Cancer· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation.
Gulshan Ara, Brynmor A Watkins, Haihong Zhong, Thomas R Hawthorne, Cyrus E Karkaria

Int J Radiat Biol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis